Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (ITCH)
The Evaluation of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Reduction of Pruritus in Alagille Syndrome, a Cholestatic Liver Disease
Sponsor: Childhood Liver Disease Research and Education Network
A PHASE2 clinical study on Alagille Syndrome, this trial is completed. The trial is conducted by Childhood Liver Disease Research and Education Network and has accumulated 9 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Dec 2018 — Apr 2019 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Childhood Liver Disease Research and Education Network
- Mirum Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .